Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04852289 · ClinicalTrials.gov registry record

A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans

A clinical trial of COVID-19, sponsored by National Institute on Aging (NIA).

Active
Registry status
78
Enrollment target
2
Study locations

NCT04852289 is a study of COVID-19 that is active but no longer recruiting, run by National Institute on Aging (NIA). The registered enrollment target is 78 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04852289, a study of COVID-19, is active but no longer recruiting, sponsored by National Institute on Aging (NIA).

ACTIVE NOT RECRUITING
Registry status
78 participants
Enrollment target
2
Study locations

Study Summary

Background: The immune response is how the body recognizes and defends itself against foreign and harmful substances. Researchers want to compare the immune responses between young and older healthy adults after they receive vaccine doses for COVID-19. This research may help to determine whether age impacts cell response to COVID-19 vaccines. Objective: To study the immune response of people who receive Pizer or Moderna COVID-19 vaccines. Eligibility: People aged 18 and older who have not had COVID-19 and who either plan to receive the first dose of a COVID-19 vaccine within the next month or have received at least the first of 2 doses of the vaccine within the last 6 months. Design: Participants will be screened by telephone. Participants will not get the COVID-19 vaccine in this study. They must get it through a vaccine location. Participants who have not yet been vaccinated will have 7 visits. The first 4 visits will occur in the first month before and after each vaccination. The last 3 visits will occur 6 months, 1 year, and 2 years after completed vaccination. Participants who have received at least 1 of 2 doses of the COVID-19 vaccine within the last 6 months will have 3 visits. The first visit will occur within 6 months of receiving the first vaccine dose. The last 2 visits will occur 1 year and 2 years after the first vaccine dose. At visits, participant will review their medical history. Their height, weight, and/or vital signs will be measured. They will give blood samples after fasting. They may give urine samples. They may have a nasal swab test for COVID-19.

Conditions Studied

COVID-19

Study Locations (2)

Maryland

  • National Institute of Aging, Clinical Research Unit - Baltimore
  • NIH/NIA/Biomedical Research Center at Johns Hopkins Bayview campus - Baltimore

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2021-04-20
Est. Completion 2027-06-30

Sponsor

National Institute on Aging (NIA)

131 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04852289

The ClinicalTrials.gov registry entry for NCT04852289 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 0 interventions.

NCT04852289 reports 2 study locations spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT04852289 about?

NCT04852289 is a clinical study titled "A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans". Background: The immune response is how the body recognizes and defends itself against foreign and harmful substances. Researchers want to compare the immune responses between young and older healthy adults after they receive vaccine doses for COVID-19. This research may help to determine whether ag...

What is the current status of trial NCT04852289?

This trial is currently active not recruiting. The enrollment target is 78 participants. The study started on 2021-04-20. Estimated completion is 2027-06-30.

What conditions does trial NCT04852289 study?

This clinical trial studies the following conditions: COVID-19.

Who is sponsoring clinical trial NCT04852289?

This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04852289 being conducted?

This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

COVID-19

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.